&nbsp;

MyPractice-Reports-Technical-Appendix-FR

Sep 2024

Regimen

MFOLFIRINOX

Cancer Type:

Gastrointestinal,

Rectal

Intent: Neoadjuvant

Drugs Used:

Quick Link(s):

Regimen Monograph

Oct 2024

Document

BMT F 047 CAR T Referral Form.pdf

Nov 2024

Document

Background.zip

Nov 2024

Regimen

MFOLFOX6+PEMB+TRAS

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Document

Biosimilar-Biologics.png

Jan 2025

Michelle Cotterchio

Senior Scientist, Acute and Hospital-Based Care, Ontario Health Senior Scientist michelle.cotterchio@ontariohealth.ca

Michelle Cotterchio

Chercheuse principale, Soins aigus et hospitaliers, Santé Ontario Chercheuse principalemichelle.cotterchio@ontariohealth.ca

Drug

bevacizumab

Other Name(s): Avastin® , Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™

Quick Link(s): Drug Monograph, Patient Info Sheet

Nov 2024

Regimen

MFOLFOX6+PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

MFOLFOX6+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used: